+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P10295(GUCA1A Antibody) at dilution 1/105. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10295(GUCA1A Antibody) at dilution 1/105. (Original magnification: ×200)    

  
  

The GUCA1A antibody is a crucial tool in studying the GUCA1A gene product, guanylate cyclase-activating protein 1 (GCAP1), which plays a vital role in retinal phototransduction. GUCA1A encodes GCAP1. a calcium-sensing regulatory protein expressed predominantly in retinal photoreceptors. GCAP1 modulates the activity of retinal membrane guanylate cyclases (RetGCs), enzymes responsible for synthesizing cyclic GMP (cGMP), a key secondary messenger in visual signaling. Under low calcium conditions (dark adaptation), GCAP1 activates RetGCs to replenish cGMP levels, enabling photoreceptor response to light. Mutations in GUCA1A are linked to inherited retinal disorders, including autosomal dominant cone dystrophy (adCD) and cone-rod dystrophy, making the antibody valuable for investigating disease mechanisms.

The GUCA1A antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect GCAP1 expression, localization, and abundance in retinal tissues or cell models. Researchers employ it to study how pathogenic mutations disrupt calcium-dependent regulation of RetGCs, leading to impaired photoreceptor function and degeneration. Its specificity ensures accurate identification of GCAP1 isoforms and post-translational modifications. Additionally, the antibody aids in evaluating therapeutic strategies targeting GUCA1A-related pathways. Commercial variants are typically raised in rabbits or mice, with validation in human and model organisms (e.g., mice, bovine), though species reactivity should be confirmed experimentally. Proper controls are essential to distinguish GCAP1 from homologous proteins like GCAP2.